OPKO Health Inc (OPK)

9.95
NASDAQ : Health Care
Prev Close 9.95
Day Low/High 0.00 / 0.00
52 Wk Low/High 7.12 / 16.90
Avg Volume 3.42M
Exchange NASDAQ
Shares Outstanding 547.44M
Market Cap 5.46B
EPS -0.10
P/E Ratio 55.39
Div & Yield N.A. (N.A)

Latest News

Weak On High Volume: Opko Health (OPK)

Weak On High Volume: Opko Health (OPK)

Trade-Ideas LLC identified Opko Health (OPK) as a weak on high relative volume candidate

Opko (OPK) Stock Gains as FDA Approves Rayaldee

Opko (OPK) Stock Gains as FDA Approves Rayaldee

Opko (OPK) stock is up this morning after the FDA approved its drug Rayaldee.

Morning Movers: BAC, MRO, NKE, OPK

Markets are projecting a positive open as Brexit-worries have abated.

'Mad Money' Lightning Round: Buy, Buy, Buy Medtronic

'Mad Money' Lightning Round: Buy, Buy, Buy Medtronic

Cramer sees Micron Technology getting back to $15 and urges caution on Holly Energy Partners.

Jim Cramer's 'Mad Money' Recap: Today's Rally Was Good but We Need More

Jim Cramer's 'Mad Money' Recap: Today's Rally Was Good but We Need More

The markets really need to see the financials, technology and healthcare sectors to move as they make up the bulk of our economy, says Jim Cramer.

OPKO Health To Host Analyst & Investor Day In New York City On June 15

OPKO Health To Host Analyst & Investor Day In New York City On June 15

OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company") announces that it will host an Analyst & Investor Day on Wednesday, June 15, 2016 beginning at 4:30 p.

Opko Health (OPK) Is Today's Strong On High Volume Stock

Opko Health (OPK) Is Today's Strong On High Volume Stock

Trade-Ideas LLC identified Opko Health (OPK) as a strong on high relative volume candidate

OPKO Health Announces Move To NASDAQ Stock Market

OPKO Health Announces Move To NASDAQ Stock Market

OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company") announces that it will move its stock exchange listing to The NASDAQ Stock Market from The New York Stock Exchange (the "NYSE").

OPKO To Discuss Draft Coverage Determinations For 4Kscore® Test At 2016 Jefferies Healthcare Conference

OPKO To Discuss Draft Coverage Determinations For 4Kscore® Test At 2016 Jefferies Healthcare Conference

OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO's 4Kscore® test at the Jefferies...

OPKO Health To Present At The 2016 Jefferies Healthcare Conference

OPKO Health To Present At The 2016 Jefferies Healthcare Conference

OPKO Health, Inc. (NYSE:OPK) today announced that senior management will present at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT).

OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination For 4Kscore® Test

OPKO Health Receives Proposed/Draft Medicare Local Coverage Determination For 4Kscore® Test

OPKO Health, Inc. (NYSE:OPK) ("OPKO" or the "Company") announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore ® Test, the only blood test that accurately identifies an...

OPKO Announces Appointment Of Douglass Laidlaw As Vice President Of Medical Affairs

OPKO Announces Appointment Of Douglass Laidlaw As Vice President Of Medical Affairs

OPKO Health, Inc. (NYSE: OPK) today announced the appointment of Douglass Laidlaw, PhD as Vice President of Medical Affairs to support the anticipated launch of RAYALDEE ®.

Biotech Gets a Lifeline

Solid earnings and the start of some M&A activity may be just what this sector needs to rise.

OPKO Announces Appointment Of Thomas Nusbickel As Senior Vice President Of Pharmaceutical Marketing And Market Access

OPKO Announces Appointment Of Thomas Nusbickel As Senior Vice President Of Pharmaceutical Marketing And Market Access

OPKO Health, Inc. (NYSE: OPK) today announced the appointment of Thomas Nusbickel as Senior Vice President of Pharmaceutical Marketing and Market Access to support the anticipated launch of RAYALDEE ®.

OPKO Health Reports First Quarter Financial And Operating Results

OPKO Health Reports First Quarter Financial And Operating Results

OPKO Health, Inc. (NYSE:OPK), a multinational biopharmaceutical and diagnostics company, today reported financial and operating results for the three months ended March 31, 2016.

Vifor Fresenius Medical Care Renal Pharma And OPKO Health Enter Into Agreement For OPKO's RAYALDEE®

Vifor Fresenius Medical Care Renal Pharma And OPKO Health Enter Into Agreement For OPKO's RAYALDEE®

Vifor Fresenius Medical Care Renal Pharma (VFMCRP), a common company of Galenica and Fresenius Medical Care, and OPKO Health (NYSE: OPK), have entered into a collaboration and license agreement for the development and...

OPKO To Announce First Quarter Operating And Financial Results On May 9, 2016

OPKO To Announce First Quarter Operating And Financial Results On May 9, 2016

OPKO Health, Inc. (NYSE: OPK), a multinational biopharmaceutical and diagnostics company, will release operating and financial results for the three months ended March 31, 2016, after the close of the U.

OPKO Presents Additional Data On RAYALDEE® At National Kidney Foundation Spring Clinical Meetings 2016

OPKO Presents Additional Data On RAYALDEE® At National Kidney Foundation Spring Clinical Meetings 2016

OPKO Health, Inc. (NYSE:OPK), announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the National Kidney Foundation...

Insiders Are Scooping Up These 5 Stocks

Insiders Are Scooping Up These 5 Stocks

Insiders at these companies have been buying shares of their own stock lately.

FDA Accepts Resubmission Of New Drug Application For RAYALDEE®

FDA Accepts Resubmission Of New Drug Application For RAYALDEE®

OPKO Health, Inc. (NYSE: OPK) today announced the U.

OPKO Announces Appointment Of James DeMarco As Senior Vice President Of Pharmaceutical Sales

OPKO Announces Appointment Of James DeMarco As Senior Vice President Of Pharmaceutical Sales

OPKO Health, Inc. (NYSE: OPK) today announced the appointment of James DeMarco as Senior Vice President of Pharmaceutical Sales to support the anticipated launch of RAYALDEE ®.

5 Stocks Insiders Love Right Now

5 Stocks Insiders Love Right Now

Insiders at these companies have been scooping up shares of their own stock lately.

OPKO Presents Additional Data On RAYALDEE® At ENDO 2016

OPKO Presents Additional Data On RAYALDEE® At ENDO 2016

OPKO Health, Inc. (NYSE:OPK), announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the Endocrine Society's 98 th...

OPKO Presents Additional Data On RAYALDEE® To Treat Secondary Hyperparathyroidism In Chronic Kidney Disease

OPKO Presents Additional Data On RAYALDEE® To Treat Secondary Hyperparathyroidism In Chronic Kidney Disease

OPKO Health, Inc. (NYSE: OPK), announced that additional data on RAYALDEE as a treatment for secondary hyperparathyroidism (SHPT) will be highlighted later today in a poster presentation at the Vitamin D Workshop, underway...

4 Big-Volume Stocks to Trade for Big Gains

4 Big-Volume Stocks to Trade for Big Gains

These stocks are seeing unusually large trading volume today. Here's what to do with them now.

Opko Health Plunges, but Still Optimistic After New Drug Fails to Get FDA OK

The FDA found no problems with the drug, but raised questions about its manufacturer.

Here's Why Opko (OPK) Stock is Plunging Today

Here's Why Opko (OPK) Stock is Plunging Today

Opko (OPK) stock is declining in early-morning trading on Wednesday after the FDA said it observed deficiencies at the company's third-party contract manufacturer.